Coherence Neuro, which is developing AI models and brain implants to help combat brain tumors, raised a $45M seed from the OpenAI Startup Fund and Founders Fund

Brain implants are now designed to improve cancer treatment based on AI-driven analysis.

Coherence Neuro, a startup developing AI models and brain implants to combat brain tumors, has secured $45 million in seed funding. The investment round was co-led by the OpenAI Startup Fund and Founders Fund. The company aims to utilize AI to decode subtle electrical signals associated with brain tumors, with the goal of detecting and potentially halting their growth. Coherence has already demonstrated the ability to detect tumor signals in animals and is transitioning to human trials. The new funding will support a clinical trial for long-term implantation in glioblastoma patients and further development of implants for other cancers. This investment highlights Big Tech's growing interest in brain data and brain-computer interfaces, seeing them as a valuable new data source for training AI models and optimizing treatments.

The significant seed funding for Coherence underscores a major trend: Big Tech's increasing investment in brain-computer interfaces (BCIs) and the data they generate. OpenAI and Founders Fund's backing of Coherence, alongside OpenAI's direct investment in Merge Labs, signals a strategic push to explore neural data as a frontier for AI development. This convergence suggests a future where AI models are trained on human brain signals, potentially leading to novel therapeutic and interactive applications.

Coherence's specific focus on using BCIs for cancer therapy, rather than solely for restoring function, presents a new paradigm in medical technology. The company's ability to detect and potentially treat tumors using AI-powered implants could redefine cancer care. This approach, which promises self-improving treatments based on real-time data, aligns with the broader industry's move toward personalized and adaptive healthcare solutions.